In this narrative review, we synthesize current evidence on classical incretins and less frequently examined gastrointestinal hormones—including PGDP beyond GLP-1 and GIP, as well as orexigenic and anorexigenic peptides—comparing individuals with obesity or T2DM with healthy controls. This evidence concerns the gene GIP and obesity disorder.